Author

A. Agami

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

B. Hooshiar Kashani· 1 shared B. Politi· 1 shared C. H. Mayr· 1 shared D. Porras-Gonzalez· 1 shared E. B. Vitner· 1 shared E. Geeraerts· 1 shared F. J. Theis· 1 shared G. Burgstaller· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

B. Hooshiar Kashani

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ex vivo tissue perturbations coupled to single cell RNA-seq reveal multi-lineage cell circuit dynamics in human lung fibrogenesis

N. J. Lang, J. Gote-Schniering, D. Porras-Gonzalez, L. Yang, L. J. De Sadeleer, R. C. Jentzsch, V. Shitov, S. Zhou, M. Ansari, A. Agami, C. H. Mayr, B. Hooshiar Kashani, Y. Chen, L. Heumos, J. C. Pestoni, , H. B. Schiller

The paper uses ex vivo perturbations on human lung slices combined with single-cell RNA-seq to study fibrogenesis, showing similarities to in vivo cell circuits and drug effects.

bioRxiv · Jan 16, 2023 · PreprintCell Biology

Antiviral activity of Glucosylceramide synthase inhibitors against SARS-CoV-2 and other RNA virus infections

E. B. Vitner, R. Avraham, H. Achdout, H. Tamir, A. Agami, L. Cherry, Y. Yahalom-Ronen, B. Politi, N. Erez, S. Melamed, N. Paran, T. Israely

The study evaluates two GCS inhibitors for antiviral activity against four enveloped RNA viruses, including SARS-CoV-2, showing broad-spectrum efficacy and improved survival in infected mice.

bioRxiv · May 18, 2020 · PreprintMicrobiology